Figure 1.

Associations between genomic testing, targeted therapy within 60 days of lung cancer diagnosis, and survival (N = 5556). Overall survival is shown by (A) genomic testing and (B) by genomic testing and treatment. The cohort was restricted to patients who survived at least 60 days after initial diagnosis of stage IV lung adenocarcinoma; exposures were ascertained during the first 60 days after diagnosis, and survival times were assessed beginning at 60 days after diagnosis. Two-sided P values were calculated from multivariable Cox proportional hazards models additionally adjusted for age at diagnosis, race, Hispanic ethnicity, sex, comorbidity (10), disability status (11,12), urban-rural status (13), marital status, Medicaid dual eligibility, area-level poverty rate, and any claim from a National Cancer Institute-designated facility. TKI = tyrosine kinase inhibitor.